Back

Tumor-Associated Macrophages Expand Chemoresistant, Ovarian Cancer Stem-Like Cells

Sharrow, A. C.; Ho, M.; Dua, A.; Buj, R.; Blenman, K. R. M.; Orsulic, S.; Buckanovich, R.; Aird, K. M.; Wu, L.

2023-10-16 cancer biology
10.1101/2023.07.17.549067 bioRxiv
Show abstract

The persistence of ovarian cancer stem-like cells (OvCSCs) after chemotherapy resistance has been implicated in relapse. However, the ability of these relatively quiescent cells to produce the robust tumor regrowth necessary for relapse remains an enigma. Since normal stem cells exist in a niche, and tumor-associated macrophages (TAMs) are the highest abundance immune cell within ovarian tumors, we hypothesized that TAMs may influence OvCSC proliferation. To test this, we optimized OvCSC enrichment by sphere culture and in vitro polarization of monocytes to a TAM-like M2 phenotype. Using cocultures that permitted the exchange of only soluble factors, we found that M2 macrophages increased the proliferation of sphere cells. Longer-term exposure (5-7 days) to soluble TAM factors led to retention of some stem cell features by OvCSCs but loss of others, suggesting that TAMs may support an intermediate stemness phenotype in OvCSCs. Although TAM coculture decreased the percentage of OvCSCs surviving chemotherapy, it increased the overall number. We therefore sought to determine the influence of this interaction on chemotherapy efficacy in vivo and found that inhibiting macrophages improved chemotherapy response. Comparing the gene expression changes in OvCSCs cocultured with TAMs to publicly available patient data identified 34 genes upregulated in OvCSCs by exposure to soluble TAM factors whose expression correlates with outcome. Overall, these data suggest that TAMs may influence OvCSC proliferation and impact therapeutic response.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Cancer Research
116 papers in training set
Top 0.1%
14.9%
2
Cell Reports
1338 papers in training set
Top 2%
10.2%
3
Cell Reports Medicine
140 papers in training set
Top 0.6%
4.9%
4
eLife
5422 papers in training set
Top 19%
4.4%
5
Stem Cell Reports
118 papers in training set
Top 0.2%
4.0%
6
JCI Insight
241 papers in training set
Top 1%
3.9%
7
Clinical Cancer Research
58 papers in training set
Top 0.4%
3.6%
8
Blood Advances
54 papers in training set
Top 0.5%
3.3%
9
npj Precision Oncology
48 papers in training set
Top 0.2%
3.1%
50% of probability mass above
10
Cancers
200 papers in training set
Top 2%
2.9%
11
Scientific Reports
3102 papers in training set
Top 45%
2.6%
12
Molecular Cancer Research
42 papers in training set
Top 0.1%
2.6%
13
Cancer Research Communications
46 papers in training set
Top 0.2%
2.5%
14
iScience
1063 papers in training set
Top 10%
2.1%
15
Communications Biology
886 papers in training set
Top 8%
1.7%
16
Oncogene
76 papers in training set
Top 1%
1.0%
17
Cell Death & Disease
126 papers in training set
Top 2%
1.0%
18
OncoImmunology
22 papers in training set
Top 0.3%
0.9%
19
Breast Cancer Research
32 papers in training set
Top 0.4%
0.9%
20
PLOS ONE
4510 papers in training set
Top 64%
0.9%
21
Stem Cells
28 papers in training set
Top 0.4%
0.8%
22
Cell Systems
167 papers in training set
Top 12%
0.8%
23
Cancer Immunology Research
34 papers in training set
Top 0.5%
0.7%
24
Journal of Leukocyte Biology
40 papers in training set
Top 0.5%
0.7%
25
Developmental Cell
168 papers in training set
Top 12%
0.7%
26
Cell Death Discovery
51 papers in training set
Top 2%
0.7%
27
The EMBO Journal
267 papers in training set
Top 7%
0.5%
28
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 1%
0.5%
29
Nature Communications
4913 papers in training set
Top 67%
0.5%
30
Journal of Biological Chemistry
641 papers in training set
Top 6%
0.5%